Literature DB >> 12821174

Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse.

Alessandro Zocchi1, Giorgia Varnier, Roberto Arban, Cristiana Griffante, Lara Zanetti, Letizia Bettelini, Mario Marchi, Philip A Gerrard, Mauro Corsi.   

Abstract

We tested fluoxetine, bupropion and GR 205171, a selective neurokinin-1 receptor antagonist on forced swimming test (FST) response and on levels of monoamines in frontal cortex of CD1 mice by microdialysis techniques. All drugs decreased immobility time. Fluoxetine augmented all monoamines, bupropion enhanced catecholamines, and GR 205171 was totally ineffective. Results suggest that FST response may not be related to levels of monoamines in the mouse frontal cortex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821174     DOI: 10.1016/s0304-3940(03)00305-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Forced swimming test in mice: a review of antidepressant activity.

Authors:  Benoit Petit-Demouliere; Franck Chenu; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.

Authors:  Cristiana Griffante; Renzo Carletti; Filippo Andreetta; Mauro Corsi
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

4.  The effects of fluoxetine and its complexes with glycerrhizic acid on behavior in rats and brain monoamine levels.

Authors:  G T Shishkina; N N Dygalo; A M Yudina; T S Kalinina; T G Tolstikova; I V Sorokina; I L Kovalenko; L V Anikina
Journal:  Neurosci Behav Physiol       Date:  2006-05

5.  Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release.

Authors:  Karl Ebner; Nicolas Singewald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-19       Impact factor: 3.000

6.  Bupropion effects on aggressiveness and anxiety in OF1 male mice.

Authors:  Rosa Redolat; M Carmen Gómez; Paloma Vicens; M Carmen Carrasco
Journal:  Psychopharmacology (Berl)       Date:  2004-07-29       Impact factor: 4.530

7.  Methylglyoxal-Mediated Dopamine Depletion, Working Memory Deficit, and Depression-Like Behavior Are Prevented by a Dopamine/Noradrenaline Reuptake Inhibitor.

Authors:  Gudrian Ricardo Lopes de Almeida; Jozimar Carlos Szczepanik; Ingrid Selhorst; Ariana Ern Schmitz; Bárbara Dos Santos; Maurício Peña Cunha; Isabella Aparecida Heinrich; Gabriela Cristina de Paula; Andreza Fabro De Bem; Rodrigo Bainy Leal; Alcir Luiz Dafre
Journal:  Mol Neurobiol       Date:  2020-10-04       Impact factor: 5.590

8.  Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.

Authors:  Olivia F O'Leary; Anita J Bechtholt; James J Crowley; Tiffany E Hill; Michelle E Page; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2007-02-21       Impact factor: 4.415

9.  Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.

Authors:  Florence Loiseau; Claudine Le Bihan; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

10.  Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.

Authors:  Katharine Pillidge; Ashley J Porter; Jared W Young; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-04-19       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.